clonidine has been researched along with Apoplexy in 16 studies
Clonidine: An imidazoline sympatholytic agent that stimulates ALPHA-2 ADRENERGIC RECEPTORS and central IMIDAZOLINE RECEPTORS. It is commonly used in the management of HYPERTENSION.
clonidine (amino form) : A clonidine that is 4,5-dihydro-1H-imidazol-2-amine in which one of the amino hydrogens is replaced by a 2,6-dichlorophenyl group.
Excerpt | Relevance | Reference |
---|---|---|
"Background and Purpose- Intrathecal baclofen (ITB) is an effective treatment for managing patients with severe poststroke spasticity, who can experience continued pain and decline in their quality of life (QoL)." | 9.27 | Effect of Intrathecal Baclofen on Pain and Quality of Life in Poststroke Spasticity. ( Abouihia, A; Calabrese, A; Cloud, G; Creamer, M; Francisco, GE; Kossmehl, P; Saltuari, L; Ward, AB; Wissel, J; Yochelson, M; Zampolini, M, 2018) |
" Treatment with tizanidine resulted in a significant improvement in pain intensity (P=0." | 9.09 | Open-label dose-titration safety and efficacy study of tizanidine hydrochloride in the treatment of spasticity associated with chronic stroke. ( Dromerick, A; Gelber, DA; Good, DC; Richardson, M; Sergay, S, 2001) |
"Tizanidine is an imidazoline central alpha(2)-adrenoceptor agonist widely used to manage spasticity secondary to conditions such as multiple sclerosis (MS), stroke, and spinal cord injury (SCI)." | 8.84 | A practical overview of tizanidine use for spasticity secondary to multiple sclerosis, stroke, and spinal cord injury. ( Henney, HR; Kamen, L; Runyan, JD, 2008) |
"The marked improvement (the decrease in spasticity, increase in muscle power and pain syndrome intensity) was noted in patients treated with the combination of tizalud and botulotoxin A." | 6.79 | [The use of tizanidine in combined treatment of arm poststroke spasticity]. ( Agafonova, NV; Khasanova, DR; Starostina, GKh, 2014) |
"A 40-year-old man developed a Horner syndrome as part of a dorsolateral medullary brainstem infarction." | 6.46 | Positive apraclonidine test 36 hours after acute onset of horner syndrome in dorsolateral pontomedullary stroke. ( Debroucker, T; Lebas, M; Seror, J, 2010) |
"Background and Purpose- Intrathecal baclofen (ITB) is an effective treatment for managing patients with severe poststroke spasticity, who can experience continued pain and decline in their quality of life (QoL)." | 5.27 | Effect of Intrathecal Baclofen on Pain and Quality of Life in Poststroke Spasticity. ( Abouihia, A; Calabrese, A; Cloud, G; Creamer, M; Francisco, GE; Kossmehl, P; Saltuari, L; Ward, AB; Wissel, J; Yochelson, M; Zampolini, M, 2018) |
"To investigate the effect of tizanidine (an alpha(2) noradrenergic agonist) on transmission in the interneuronal pathway coactivated by group I and group II afferents in post-stroke patients with spastic hemiplegia." | 5.11 | Modulation of the transmission in group II heteronymous pathways by tizanidine in spastic hemiplegic patients. ( Marque, P; Maupas, E; Roques, CF; Simonetta-Moreau, M, 2004) |
" Treatment with tizanidine resulted in a significant improvement in pain intensity (P=0." | 5.09 | Open-label dose-titration safety and efficacy study of tizanidine hydrochloride in the treatment of spasticity associated with chronic stroke. ( Dromerick, A; Gelber, DA; Good, DC; Richardson, M; Sergay, S, 2001) |
"Tizanidine is an imidazoline central alpha(2)-adrenoceptor agonist widely used to manage spasticity secondary to conditions such as multiple sclerosis (MS), stroke, and spinal cord injury (SCI)." | 4.84 | A practical overview of tizanidine use for spasticity secondary to multiple sclerosis, stroke, and spinal cord injury. ( Henney, HR; Kamen, L; Runyan, JD, 2008) |
"At baseline, weeks 1, 3 and 12, spasticity was assessed and compared between the two groups using Modified Ashworth Scale (MAS), clonus score, passive range of motion (ROM) of joint, pain score, 3-m walk duration and lower extremity functional score (LEFS)." | 2.84 | Effect of Extracorporeal Shock Wave Therapy on Lower Limb Spasticity in Stroke Patients. ( Akbari, M; Ashtari, F; Mellat, M; Taheri, P; Vahdatpour, B, 2017) |
"The marked improvement (the decrease in spasticity, increase in muscle power and pain syndrome intensity) was noted in patients treated with the combination of tizalud and botulotoxin A." | 2.79 | [The use of tizanidine in combined treatment of arm poststroke spasticity]. ( Agafonova, NV; Khasanova, DR; Starostina, GKh, 2014) |
"A 40-year-old man developed a Horner syndrome as part of a dorsolateral medullary brainstem infarction." | 2.46 | Positive apraclonidine test 36 hours after acute onset of horner syndrome in dorsolateral pontomedullary stroke. ( Debroucker, T; Lebas, M; Seror, J, 2010) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 7 (43.75) | 29.6817 |
2010's | 9 (56.25) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Taheri, P | 1 |
Vahdatpour, B | 1 |
Mellat, M | 1 |
Ashtari, F | 1 |
Akbari, M | 1 |
Duncan, D | 1 |
Sankar, A | 1 |
Beattie, WS | 1 |
Wijeysundera, DN | 1 |
Creamer, M | 1 |
Cloud, G | 1 |
Kossmehl, P | 1 |
Yochelson, M | 1 |
Francisco, GE | 1 |
Ward, AB | 1 |
Wissel, J | 1 |
Zampolini, M | 1 |
Abouihia, A | 1 |
Calabrese, A | 1 |
Saltuari, L | 1 |
Lipták, J | 1 |
Khasanova, DR | 1 |
Agafonova, NV | 1 |
Starostina, GKh | 1 |
Esin, RG | 1 |
Sitnova, MA | 1 |
Esin, OR | 1 |
Lindsay, C | 1 |
Kouzouna, A | 1 |
Simcox, C | 1 |
Pandyan, AD | 1 |
Sheean, G | 1 |
Lebas, M | 1 |
Seror, J | 1 |
Debroucker, T | 1 |
De Benedictis, L | 1 |
Dumais, A | 1 |
Landry, P | 1 |
Oliveira-Filho, J | 1 |
Silva, SC | 1 |
Trabuco, CC | 1 |
Pedreira, BB | 1 |
Sousa, EU | 1 |
Bacellar, A | 1 |
Maupas, E | 1 |
Marque, P | 1 |
Roques, CF | 1 |
Simonetta-Moreau, M | 1 |
Schrader, J | 1 |
Diener, HC | 1 |
Lüders, S | 1 |
Yelnik, AP | 1 |
Kamen, L | 1 |
Henney, HR | 1 |
Runyan, JD | 1 |
Gelber, DA | 1 |
Good, DC | 1 |
Dromerick, A | 1 |
Sergay, S | 1 |
Richardson, M | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Impact of Intraoperative Goal-directed Blood Pressure Management and Dexmedetomidine on Outcomes of High-risk Patients After Major Abdominal Surgeries: a 2×2 Factorial Randomized Controlled Trial[NCT03933306] | Phase 4 | 496 participants (Actual) | Interventional | 2019-05-20 | Active, not recruiting | ||
A Randomized, Controlled, Open-label, Parallel-group, Multi-center Study to Compare the Effect of Intrathecal Baclofen Therapy Versus Best Medical Treatment on Severe Spasticity in Post-stroke Patients After 6 Months Active Treatment[NCT01032239] | Phase 4 | 61 participants (Actual) | Interventional | 2009-11-30 | Completed | ||
Effects of Neuromuscular Electrical Stimulation on Walking Ability and Quality of Life in Individuals With Chronic Stroke[NCT04673045] | 40 participants (Anticipated) | Interventional | 2021-02-02 | Recruiting | |||
Comparison of Peripheral and Cerebral Arterial Flow in Acute Ischemic Stroke: Fimasartan vs. Valsartan vs. Atenolol[NCT02403349] | Phase 4 | 105 participants (Actual) | Interventional | 2012-05-31 | Active, not recruiting | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Change in average 10MTWT from baseline to month 6 beetween ITB and BMT arm. Change=10MTWT at month 6 - 10MTWT at baseline (NCT01032239)
Timeframe: Baseline and month 6
Intervention | seconds (Mean) |
---|---|
ITB Therapy | 4.86 |
Best Medical Treatment (BMT) | -2.48 |
"AS is a manual test, measuring the resistance to passive movement about a joint with varying degrees of velocity. Scores range from 1-5, with 5 choices. A score of 1 indicates no resistance, and 5 indicates rigidity. The following muscle groups in the lower extremities were assessed: hip flexors, hip adductors, knee extensors, knee flexors, plantar flexors and ankle-dorsal flexors. Average AS was calculated as the average of AS scores of the 6 muscles of the affected lower extremity. Change in average AS in affected lower extremities from baseline to month 6 between ITB and BMT arm was assessed.~Change= AS at month 6 - AS at baseline." (NCT01032239)
Timeframe: Baseline and month 6
Intervention | units on a scale (Mean) |
---|---|
ITB Therapy | -0.99 |
Best Medical Treatment (BMT) | -0.43 |
"AS is a manual test, measuring the resistance to passive movement about a joint with varying degrees of velocity. Scores range from 1-5, with 5 choices. A score of 1 indicates no resistance, and 5 indicates rigidity. The following muscle groups in the upper extremities were assessed: wrist flexors, elbow flexors, elbow extensors, shoulder abductors and shoulder adductors. Average AS was calculated as the average of AS scores of the 5 muscles of the affected lower extremities. Change in average AS in affected upper extremities from baseline to month 6 between ITB and BMT arm was assessed.~Change= AS at month 6 - AS at baseline." (NCT01032239)
Timeframe: Baseline and month 6
Intervention | units on a scale (Mean) |
---|---|
ITB Therapy | -0.66 |
Best Medical Treatment (BMT) | -0.17 |
FIM contains 18 items composed of 13 motor tasks and 5 cognitive tasks. Tasks are rated on a 7-point ordinal scale that ranges from total assistance (or complete dependence) to complete independence. Ratings should reflect actual observed performance, not capability. Total score ranges from 18 (lowest) to 126 (highest) level of independence. Change in FIM total score from baseline to month 6 between ITB and BMT arm was assessed. Change=FIM score at month 6 - FIM score at baseline. (NCT01032239)
Timeframe: Baseline and month 6
Intervention | units on a scale (Mean) |
---|---|
ITB Therapy | 2.68 |
Best Medical Treatment (BMT) | -2.58 |
"SS-QoL questionnaire is a self-assessed quality of life questionnaire specifically designed for post-stroke patients. It evaluates 49 items across 12-domains: personality, energy, language, mobility, vision, upper extremity function, thinking, mood, work/productivity, self-care, and family and social roles. Each item is rated on a 5-point Likert Scale, measuring either positive or negative response to a statement. Summary score is composed of an unweighted average of the 12 domain scores, with higher scores indicating better QoL. Total score ranges from 1 to 5. Change in SS-QoL summary score from baseline to month 6 between ITB and BMT arm was assessed.~Change=SS-QoL score at month 6 - SS-QoL score at baseline." (NCT01032239)
Timeframe: Baseline and month 6
Intervention | units on a scale (Mean) |
---|---|
ITB Therapy | 0.26 |
Best Medical Treatment (BMT) | 0.05 |
"The EQ-5D-3L is a generic measure of health status consisting in the EQ-5D-3L descriptive system and the EQ visual analogue scale (EQ VAS). The EQ-5D-3L descriptive system is characterized on five dimensions: mobility, self-care, ability to undertake usual activities, pain and anxiety/depression. Patients were asked to indicate their level of health on each dimension using one of three levels: no health problems, moderate health problems, and severe health problems. Responses from the questionnaire were converted to a single health index utility score; this ranges from -0.595 to 1. EQ VAS records the patient's self-rated health on a vertical visual analogue scale from 0 to 100 where the endpoints are labelled 'Best imaginable health state' (100) and 'Worst imaginable health state' (0). Change in EQ-5D-3L utility score and VAS score from baseline to month 6 between ITB and BMT arm were assessed. Change=EQ-5D-3L utility or VAS score at month 6 - EQ-5D-3L utility or VAS score." (NCT01032239)
Timeframe: Baseline and month 6
Intervention | units on a scale (Mean) | |
---|---|---|
Utility Score | VAS | |
Best Medical Treatment (BMT) | 0.01 | 4.40 |
ITB Therapy | 0.09 | 9.68 |
"NPRS is designed to assess the level of pain a patient is feeling at a point in time. The following questions has been presented to patients: What is your actual spasticity-related or spasm-related pain? What was your least spasticity-related or spasm-related pain during the last week? What was your worst spasticity-related or spasm-related pain during the last week? The patient indicated how much pain he is feeling on a scale from 0 to 10. A score of 0 (zero) is no pain while a score of 10 (ten) is worst possible pain. Change in NPRS related to actual, least or worst pain from baseline to month 6 between ITB and BMT arm was assessed. Change=NPRS at month 6 - NPRS at baseline." (NCT01032239)
Timeframe: Baseline and month 6
Intervention | units on a scale (Mean) | ||
---|---|---|---|
Actual pain | Least Pain | Worst Pain | |
Best Medical Treatment (BMT) | 0.00 | 0.24 | -0.04 |
ITB Therapy | -1.17 | -1.61 | -1.35 |
The SF-12 is generic assessment of health-related quality of life, which evaluates 8 health dimensions (physical functioning, role physical, bodily pain, vitality, social functioning, role emotional, mental health, and general health). Subscale scores for each dimension were aggregated into summary scores for physical (PCS) and mental health (MCS) components (ranging from 0 to 100, with higher scores indicating better health). Changes in the PCS and MCS from baseline to Month 6 were both compared between the BMT and ITB arms. Change=SF-12 score at month 6 - SF-12 score at baseline. (NCT01032239)
Timeframe: Baseline and month 6
Intervention | units on a scale (Mean) | |
---|---|---|
PCS | MCS | |
Best Medical Treatment (BMT) | -1.13 | -0.82 |
ITB Therapy | 3.13 | 1.05 |
Number of patients with healthcare professional contacts outside of study visits in the ITB and BMT between baseline and months 6 (NCT01032239)
Timeframe: baseline, ITB test (only ITB arm), second assessment (only BMT arm), week 6 (only ITB arm), month 3, month 6
Intervention | Participants (Count of Participants) | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Baseline : general practitioner | Baseline : neurologist | Baseline : nurse (hospital setting) | Baseline : nurse (home care) | Baseline : orthopedic surgeon | Baseline : other | ITB test:general practitioner | ITB test: neurologist | ITB test :other | Second Assessment: general practitioner | Second Assessment: neurologist | Second Assessment: nurse (home care) | Second Assessment: other | week 6: general practitioner | week 6: nurse (hospital setting) | week 6: other | month 3: general practitioner | month 3: neurologist | month 3: other | month 6: general practitioner | month 6: neurologist | month 6: other | |
Best Medical Treatment (BMT) | 8 | 8 | 0 | 1 | 0 | 13 | NA | NA | NA | 5 | 1 | 1 | 4 | NA | NA | NA | 8 | 3 | 9 | 7 | 2 | 11 |
ITB Therapy | 14 | 4 | 1 | 0 | 3 | 10 | 1 | 1 | 3 | NA | NA | NA | NA | 4 | 2 | 2 | 7 | 1 | 6 | 8 | 3 | 8 |
Patient was asked to transfer from the wheelchair to bed without human assistance. High level functional patient (HLP) could transfer. Low level functional patient (LLP) was not able to transfer. Comparison of the number and percentage of HLP and LLP between ITB and BMT arms was evaluated. (NCT01032239)
Timeframe: baseline, month 3, month 6
Intervention | Participants (Count of Participants) | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Baseline72364475 | Baseline72364476 | Month 372364475 | Month 372364476 | Month 672364475 | Month 672364476 | |||||||
HLP | LLP | |||||||||||
ITB Therapy | 22 | |||||||||||
Best Medical Treatment (BMT) | 24 | |||||||||||
ITB Therapy | 9 | |||||||||||
Best Medical Treatment (BMT) | 21 | |||||||||||
ITB Therapy | 6 | |||||||||||
ITB Therapy | 19 | |||||||||||
Best Medical Treatment (BMT) | 19 | |||||||||||
ITB Therapy | 5 | |||||||||||
Best Medical Treatment (BMT) | 5 |
"Patients were presented with two statements (I am satisfied with the reduction in spasticity provided by my treatment, and I would recommend this therapy to a friend). They agreed, disagreed or were neutral with the statements." (NCT01032239)
Timeframe: month 6
Intervention | Participants (Count of Participants) | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Patient Satisfaction with Spasticity Reduction72364475 | Patient Satisfaction with Spasticity Reduction72364476 | Patient Therapy Reccomandation72364475 | Patient Therapy Reccomandation72364476 | |||||||||
disagree | neutral | agree | ||||||||||
ITB Therapy | 2 | |||||||||||
Best Medical Treatment (BMT) | 7 | |||||||||||
ITB Therapy | 4 | |||||||||||
ITB Therapy | 16 | |||||||||||
Best Medical Treatment (BMT) | 11 | |||||||||||
Best Medical Treatment (BMT) | 5 | |||||||||||
ITB Therapy | 3 | |||||||||||
Best Medical Treatment (BMT) | 4 | |||||||||||
Best Medical Treatment (BMT) | 14 |
5 reviews available for clonidine and Apoplexy
Article | Year |
---|---|
Alpha-2 adrenergic agonists for the prevention of cardiac complications among adults undergoing surgery.
Topics: Adrenergic alpha-Agonists; Clonidine; Dexmedetomidine; Heart Diseases; Humans; Imidazoles; Intraoper | 2018 |
Pharmacological interventions other than botulinum toxin for spasticity after stroke.
Topics: Baclofen; Botulinum Toxins, Type A; Clonidine; Diazepam; Humans; Muscle Relaxants, Central; Muscle S | 2016 |
Positive apraclonidine test 36 hours after acute onset of horner syndrome in dorsolateral pontomedullary stroke.
Topics: Adrenergic alpha-Agonists; Adult; Clonidine; Horner Syndrome; Humans; Magnetic Resonance Angiography | 2010 |
[Pharmacology and upper limb poststroke spasticity: a review. International Society of Prosthetics and Orthotics].
Topics: Arm; Baclofen; Botulinum Toxins, Type A; Clonidine; Combined Modality Therapy; Dantrolene; Ergonomic | 2004 |
A practical overview of tizanidine use for spasticity secondary to multiple sclerosis, stroke, and spinal cord injury.
Topics: Brain Injuries; Clonidine; Disease Progression; Drug Interactions; Female; Humans; Middle Aged; Mult | 2008 |
6 trials available for clonidine and Apoplexy
Article | Year |
---|---|
Effect of Extracorporeal Shock Wave Therapy on Lower Limb Spasticity in Stroke Patients.
Topics: Adult; Aged; Clonidine; Extracorporeal Shockwave Therapy; Female; Humans; Iran; Male; Middle Aged; M | 2017 |
Effect of Intrathecal Baclofen on Pain and Quality of Life in Poststroke Spasticity.
Topics: Administration, Oral; Aged; Baclofen; Benzodiazepines; Clonidine; Dantrolene; Female; Humans; Infusi | 2018 |
[The use of tizanidine in combined treatment of arm poststroke spasticity].
Topics: Anticonvulsants; Arm; Botulinum Toxins, Type A; Clonidine; Female; Humans; Male; Muscle Spasticity; | 2014 |
Detrimental effect of blood pressure reduction in the first 24 hours of acute stroke onset.
Topics: Acute Disease; Antihypertensive Agents; Blood Pressure; Captopril; Clonidine; Female; Humans; Hypert | 2003 |
Modulation of the transmission in group II heteronymous pathways by tizanidine in spastic hemiplegic patients.
Topics: Administration, Oral; Adrenergic alpha-Agonists; Adult; Aged; Clonidine; Female; Hemiplegia; Humans; | 2004 |
Open-label dose-titration safety and efficacy study of tizanidine hydrochloride in the treatment of spasticity associated with chronic stroke.
Topics: Clonidine; Dose-Response Relationship, Drug; Female; Hand Strength; Humans; Male; Middle Aged; Muscl | 2001 |
5 other studies available for clonidine and Apoplexy
Article | Year |
---|---|
[Comparative effectiveness of different muscle relaxants in the rehabilitation of post-stroke patients with spasticity].
Topics: Aged; Baclofen; Clonidine; Comparative Effectiveness Research; Dantrolene; Female; Humans; Male; Mus | 2013 |
[The principles of pharmacotherapy of poststroke shoulder pain].
Topics: Amines; Amitriptyline; Anti-Inflammatory Agents; Clonidine; Cyclohexanecarboxylic Acids; Drug Therap | 2015 |
Botulinum toxin should be first-line treatment for poststroke spasticity.
Topics: Anti-Dyskinesia Agents; Botulinum Toxins; Clonidine; Humans; Muscle Relaxants, Central; Muscle Spast | 2009 |
Successful treatment of severe disruptive disorder featuring symptoms of the Klüver-Bucy Syndrome following a massive right temporal-parietal hemorrhage.
Topics: Adrenergic alpha-Agonists; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Di | 2013 |
[Treating high blood pressure in acute stroke].
Topics: Acute Disease; Adrenergic alpha-Agonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Conve | 2004 |